Tumors erbb 2 receptor erbb 2. Medical search. Frequent questions

MammaPrint/BluePrint subtyping classified patients into four molecular subgroups: Luminal A, Luminal B, HER2 (human epidermal growth factor receptor 2), and Basal type. (nih.gov)
The ErbB protein family consists of 4 members ErbB-1, also named epidermal growth factor receptor (EGFR) ErbB-2, also named HER2 in humans and neu in rodents ErbB-3, also named HER3 ErbB-4, also named HER4 v-ErbBs are homologous to EGFR, but lack sequences within the ligand binding ectodomain. (wikipedia.org)
ERBB2 is a protein that is also known as HER2 (human epidermal growth factor receptor 2). (antibodyguide.com)
Triple-negative breast cancer (TNBC) is any breast cancer that does not express the genes for estrogen receptor (ER), progesterone receptor (PR) and Her2/neu [ 1 ]. (oncotarget.com)
The objective of this study was to determine the conversion rate of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER) and progesterone receptor (PR) between primary tumors and metastatic lesions in advanced breast cancer. (springer.com)
There was substantial agreement regarding the expression of HER2 in primary tumors and metastases, and ER at metastases, between local and central laboratories. (springer.com)
The status of human epidermal growth factor receptor 2 (HER2) and the hormone receptors (HR), including estrogen receptor (ER) and progesterone receptor (PR), are the most relevant biomarkers for clinical practice, predicting response to anti-HER2 and endocrine therapies, respectively. (springer.com)
Recently, the 12th St Gallen International Breast Cancer Conference Expert Panel recommends that the subtype classification of breast cancer, namely 'HR positive' (including 'luminal A' and 'luminal B' tumors), 'HER2 amplified' and 'triple negative,' should guide the treatment plan for breast cancer patients. (springer.com)
Being aware of the benefits that the correct systemic therapy provides to patients with advanced breast cancer, the Spanish Breast Cancer Research Group (GEICAM) performed a prospective, observational study to determine the conversion rate of receptor status (ER, PR and HER2) between the primary tumor and the recurrent lesion. (springer.com)
With the addition of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), improvements in overall survival have been observed among patients with advanced HER2-positive disease. (carcinogenesis.com)
We also review the data the efficacy and safety of anthracycline-based and nonanthracycline-based adjuvant chemotherapy regimens combined with trastuzumab, and optimum chemotherapy regimens in small HER2-positive tumors. (carcinogenesis.com)
One type of breast cancer is identified by the human epidermal growth factor receptor 2 (HER2) gene amplification. (carcinogenesis.com)
HER2 is a member of the cErbB family of receptor tyrosine kinases, and is responsible for HER2-mediated signal transduction in the cytoplasm. (carcinogenesis.com)
Dr. Tahover and her colleagues' review in this issue of "Harefuah" presents the pivotal trials that have brought a change of practice in the adjuvant treatment of patients with breast cancer and HER2 positive tumors. (tau.ac.il)
HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies. (ox.ac.uk)
Paraffin wax sections of 70 surgically resected colorectal adenocarcinomas were examined for the overexpression of HER2/c-erbB-2 oncoprotein using three different specific antibodies and the avidin-biotin immunoperoxidase technique. (ox.ac.uk)
Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. (ox.ac.uk)
PURPOSE: The purpose of the study was to investigate the associations between uptake of (111)In-DTPA-trastuzumab, tumour HER2 density and response to trastuzumab (Herceptin) of human breast cancer (BC) xenografts in athymic mice. (ox.ac.uk)
MATERIALS AND METHODS: The tumour uptake of (111)In-DTPA-trastuzumab in athymic mice bearing BC xenografts with increasing HER2 density (0 to 3+) was evaluated. (ox.ac.uk)
r (2) = 0.87), but without these corrections, the association between HER2 density and tumour uptake was poor (r (2) = 0.22). (ox.ac.uk)
There was a strong association between ROI-SUR and ROI-LI values and HER2 expression (r (2) = 0.90 and r (2) = 0.95, respectively. (ox.ac.uk)
Relative TGI values were associated with increasing uncorrected tumour uptake of (111)In-DTPA-trastuzumab but not always with HER2 density (i.e. (ox.ac.uk)
CONCLUSION: HER2 expression (0 to 3+) can be differentiated using (111)In-DTPA-trastuzumab, but requires correction of tumour uptake for nonspecific IgG localization and circulating radioactivity. (ox.ac.uk)
Receptor tyrosine-protein kinase ERBB-2 (HER2 - human epidermal growth factor receptor 2) is considered as a marker of aggressiveness in the case of breast cancer in primary tumours as well as in corresponding metastases. (biomedres.us)
It is a member of the ErbB receptor family, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). (promab.com)
HER2 positive breast cancer is identified by the overexpression of human epidermal growth factor receptor-2 (HER2) protein in tumor tissue and results in an increased rate of cell proliferation. (her2support.org)
The HER Alosetron family is comprised of four unique receptors: EGFR (also known as HER1 or ErbB-1) HER2 (ErbB-2 Neu) HER3 (ErbB-3) and HER4 (ErbB-4). (ecolowood.com)
HER2 does not have any identified ligand an undeniable fact explained from the structure from the extracellular area from the receptor which is already in an activated conformation and does not allow ligand docking. (ecolowood.com)
capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab . (hdkino.org)
letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (hdkino.org)
In particular, HER2 and HER3 are over-expressed in 23277-43-2 IC50 a number of tumors, and their expression levels are associated with abnormal growth and poor clinical prognosis. (researchhunt.com)
While this has led to the development of a range of therapeutics targeting the HER2 receptor [15], the use of these drugs can often lead to resistance through a diverse set of mechanisms [16]. (researchhunt.com)
Patients with breast cancer positive for human epidermal growth-factor receptor type 2 (HER2) are an important subgroup for consideration in the Asian context. (mcmaster.ca)
1 The human epidermal growth factor receptor 2 (HER2 or ErbB2) is a tyrosine kinase receptor that belongs to the EGFR (ErbB) family and is sometimes implicated in breast, lung, and other cancers. (mdforlives.com)
An estimated 2-6% of NSCLC cases have a mutation in the HER2 oncogene, and others have overexpression or amplification of HER2. (mdforlives.com)
Human epidermal growth factor receptor 2 (HER2) bound to a targeted therapeutic agent. (mdforlives.com)
Antibody-drug conjugates are finding success in Phase 2 clinical trials for the treatment of NSCLC that involves HER2 overexpression or HER2 mutation. (mdforlives.com)
In one study, about 1 in 5 people with stomach cancer had tumors that were HER2-positive (or HER2+). (opiatalk.com)
Tumor Her2/ neu is generally assessed as protein overexpression by using immunohistochemistry (IHC), and patients with tumors that either have 2+ or 3+ results with this method become good candidates for treatment with trastuzumab. (biomedcentral.com)
While traditional, routinely measured biomarkers such as estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2) still represent the best prognostic and predictive biomarkers for HR+ breast cancer, a significant proportion of patients either do not respond to endocrine therapy or develop endocrine resistant disease. (ox.ac.uk)

The ErbB family of proteins contains four receptor tyrosine kinases, structurally related to the epidermal growth factor receptor (EGFR), its first discovered member. (wikipedia.org)
It is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. (antibodyguide.com)
GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2. (rcsb.org)
Surprisingly, we found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa). (rcsb.org)
c- erb B-2 (HER-2/ neu ) is a 185 kDa receptor tyrosine kinase belonging to the epidermal growth factor receptor family, which also includes EGFR (HER-1), c- erb B-3 (HER-3), and c- erb B-4 (HER-4). (ihcworld.com)
Neratinib is an irreversible inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2) tyrosine kinases by targeting a cysteine residue in the ATP-binding site of the receptor. (lclabs.com)
Neratinib inhibits the proliferation of HER-2 overexpressing human breast cancer cell lines and EGFR-dependent cells in vitro. (lclabs.com)
In vivo, neratinib is active against HER-2- and EGFR-dependent tumor xenograft models. (lclabs.com)
It has been proposed that oncogenes (EGFR (ERBB), MET) and tumor suppressors (PTEN, TP53) may also be capable of altering the vesicular release of tissue factor (TF) from cells [4-6]. (biomedres.us)
The ErbB-2 proto-oncogene, also called Neu, EGFR-2 or HER-2, is a member of the transmembrane receptor tyrosine kinase family, which also includes EGF receptor and EGFR-3 (HER-3 or ErbB-3). (activemotif.com)
EGFR is type I receptor tyrosine kinase with sequence homology to erbB-1, -2, -3 -4 or HER-1, -2, -3 -4. (neobiotechnologies.com)
EGFR (Epidermal growth factor receptor, HER1, ErbB1) is encoded by the EGFR gene located on chromosome 7 in humans. (thermofisher.com)
EGFR belongs to the HER/ERbB family of proteins that includes three other receptor tyrosine kinases, ERbB2, ERbB3, ERbB4. (thermofisher.com)
EGFR is a transmembrane receptor and binding of its cognate ligands such as EGF (Epidermal Growth Factor) and TGF alpha (Transforming Growth Factor alpha) to the extracellular domain leads to EGFR dimerization followed by autophosphorylation of the tyrosine residues in the cytoplasmic domain. (thermofisher.com)
Phosphorylation of EGFR at certain residues is also mediated by Src-non-receptor kinase. (thermofisher.com)
Upon receptor activation and signaling, EGFR is endocytosed and targeted for degradation or recycling. (thermofisher.com)
Increased production or activation of EGFR has been associated with poor prognosis in a variety of tumors. (thermofisher.com)
EGFR (epidermal growth factor receptor) is a transmembrane protein and receptor for members of the epidermal growth factor (EGF) family of extracellular protein ligands. (promab.com)
Defective signaling of EGFR and other receptor tyrosine kinases in humans has been linked to diseases such as Alzheimer's disease, while overexpression has been linked to the development of various tumors. (promab.com)
Disruption of EGFR signaling by blocking the EGFR-binding site on the extracellular domain of the receptor or inhibiting intracellular tyrosine kinase activity prevents the growth of EGFR-expressing tumors and improves patient outcomes. (promab.com)
The anti-EGFR CAR in this product is approximately 56 kD and consists of anti-EGFR scFv (single-chain variable fragment) linked to a second-generation CAR (chimeric antigen receptor) containing the CD8 hinge and transmembrane domain and 4-1BB and CD3ζ signaling domains. (promab.com)
The epidermal growth factor receptor (EGFR) continues to be implicated in head and neck squamous cell carcinoma (HNSCC) carcinogenesis. (ecolowood.com)
If ultimately shown to reduce the risk of oral tumor chemoprevention with EGFR inhibitors may significantly reduce morbidity and possibly mortality from HNSCC. (ecolowood.com)
They may be created as transmembrane precursors and could become subdivided into three organizations according with their affinity for just one or even more HER receptors: the 1st group includes ligands that bind specifically to EGFR (e.g. (ecolowood.com)
Once activated these pathways contribute to the development of a malignant cellular phenotype including resistance to apoptosis increased proliferation invasion metastasis and stimulation of angiogenesis (Figure 1).1 Figure 1 Epidermal growth factor receptor (EGFR) pathway activation during HNSCC carcinogenic process. (ecolowood.com)
Loss of heterozigosity (LOH) EGFR overexpression/amplification and cyclooxygenase-2 (COX2) dysregulation in pre-malignant lesions have been associated with … The EGFR has been implicated in head and neck squamous cell carcinoma (HNSCC) carcinogenesis. (ecolowood.com)
AboulWafa OM, Daabees HMG, Badawi WA (2020) 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study. (dntb.gov.ua)
Akhtar MJ, Khan AA, Ali Z et al (2018) Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors. (dntb.gov.ua)
Epidermal growth factor receptor ( EGFR , ErbB ) gene mutations are one of the most well-researched targets for lung cancer treatment. (mdforlives.com)
1,2 EGFR tyrosine kinase inhibitors (EGFR TKI) are used as first-line treatments in advanced NSCLC cases where EGFR mutations are present. (mdforlives.com)
1,2 Patritumab deruxtecan (HER3-DXd/U3-1402) is a HER3-targeted antibody-drug conjugate that showed anti-tumor activity and acceptable safety in patients with advanced NSCLC who are on EGFR TKI. (mdforlives.com)
2,13 Monoclonal antibodies against programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) are effective treatment options for a relatively small percentage of patients with NSCLC, but they are not recommended for patients with EGFR-mutated NSCLC. (mdforlives.com)
HER-2 (ErbB2) is a 185-kDa transmembrane tyrosine kinase with extensive homology to the epidermal growth factor receptor (EGFR). (touchoncology.com)

32 % of patients exhibited overexpression of HER-2/neu. (thieme-connect.de)
Prospective studies correlating HER-2/neu overexpression with prognosis might provide additional data. (thieme-connect.de)
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. (thieme-connect.de)
Amplification of the HER-2 gene with overexpression of the protein occurs in 20-30% of breast cancers, and tumor progression in mammary cancer is associated with elevated levels of tyrosine-phosphorylated neu and erbB-3. (ihcworld.com)
It is suggested that the overexpression of c-erbB-2 gene product is unlikely to be as common and as pronounced in colorectal adenocarcinoma as it is in ductal carcinoma of the breast. (ox.ac.uk)
In particular, the overexpression of ERBB2 enhances the properties of tumour cells associated with increased cancer metastasis (invasiveness, angiogenicity, enhanced survival). (biomedres.us)
Although, ErbB-2 does not have any known high-affinity ligands, its kinase activity can be activated without ligand by either overexpression or heteroassociation with other members of the ErbB family. (activemotif.com)
Amplification of the ErbB-2 gene and overexpression of its product has been detected in almost 40% of primary human breast tumors, which correlates with poor prognosis in node positive breast cancer. (activemotif.com)
ErbB-2 overexpression is also observed in ovarian, gastric, salivary and non-small cell lung carcinomas. (activemotif.com)
Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. (cdc.gov)
Given the importance of erbB-2 in human breast cancer, the finding of erbB-2 overexpression in canine OSA may be important in further understanding the pathogenesis and possible therapies of OSA. (cdc.gov)
The epidermal growth factor receptor (ERBB1) and related family member HER-2/ neu (ERBB2) are often overexpressed in aggressive breast cancers and their overexpression is correlated with poor prognosis. (aacrjournals.org)
While it has been recognised for some time that overexpression of HER-2 is a poor prognostic factor in breast cancer, it was the advent of trastuzumab, a humanised monoclonal antibody directed against the extracellular domain of HER-2, that has allowed clinicians to better understand the natural history of HER-2-positive metastatic breast cancer. (touchoncology.com)
In 20-30% of breast carcinomas, Her-2/ neu status is altered, and this is manifested either as amplification of the gene or overexpression of the protein product [ 3 ]. (biomedcentral.com)

More than 10,000 patients with tumors that were defined as human epidermal growth factor receptor 2, ErbB-2 positive have been recruited into these trials. (tau.ac.il)
The status of the erbB-2 (human epidermal growth factor receptor 2/neu) proto-oncogene in canine osteosarcoma (OSA) has not been reported previously. (cdc.gov)
Also called c-erbB-2 positive and human epidermal growth factor receptor 2 positive. (opiatalk.com)

Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. (rochester.edu)
The enhancement in metastatic properties was also found to occur via activation of ERBB2 receptor signaling pathways [2]. (biomedres.us)
The finding is the first time shown pro-tumour gene ERBB2 enable to modulate coagulation protein expression and clotting kinetics in breast cancer cells, it is via the PI3k/Akt pathways, which further supports the proposal that the state of the coagulation system in cancer is directly influenced by oncogenic transformation. (biomedres.us)
ErbB2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of human cancers , including cancers of the breast. (her2support.org)
Using in vivo mouse models of breast cancer, we test the effects of ERBB1 and ERBB2 inhibitors AC480 and lapatinib, ERBB1 inhibitor gefitinib, and ERBB2 inhibitor AG825 on in vivo tumor cell invasive properties in mammary fat pad tumors. (aacrjournals.org)
ERBB1 and ERBB2 inhibition rapidly (within 3 h) inhibits both tumor cell motility and intravasation. (aacrjournals.org)
Using gefitinib, ERBB1 inhibition rapidly inhibits tumor cell motility and invasion but not intravasation, whereas ERBB2 inhibition by AG825 rapidly blocks intravasation. (aacrjournals.org)
ERBB1 and ERBB2 inhibition can rapidly block tumor cell invasive properties. (aacrjournals.org)
In addition, we differentiate for the first time the contributions of ERBB1 and ERBB2 to the key metastatic properties of in vivo tumor cell invasion and intravasation. (aacrjournals.org)

Reasons for these discrepancies may include the possibility that the molecular profile of breast cancers evolves over time and that biomarkers are heterogeneously expressed within the tumor [ 4 ] and technical inconsistencies in both tissue processing and sample evaluation. (springer.com)
Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. (ox.ac.uk)

Patients who maintained high immunoreactivity for anti-MUC1 antibody had a better prognosis, whereas those with an increase in anti-MUC3 immunoreactivity had a poorer prognosis, as judged by tumour size, serosal invasion, and metastasis. (bmj.com)
1, 2 Most studies of MUC1 expression in breast carcinomas have shown that increased membrane MUC1 mucin expression on the apical cell surface is associated with a better prognosis (reviewed in Rahn and colleagues 2 ), whereas circumferential staining in tumour cell cytoplasm is associated with a worse prognosis. (bmj.com)
The HER-2/neu onkogene may play a role in the prognosis and management of patients with breast cancer. (thieme-connect.de)
5 Beckmann M W, Niederacher D, Schnurch H G, Bender H G. The erbB gene family: significance for tumor development, prognosis and new therapeutic modalities. (thieme-connect.de)
While the importance 23277-43-2 IC50 of HER expression levels has been established for clinical prognosis and drug resistance, the mechanistic link between receptor expression, HER activation and downstream consequences is not as clear yet. (researchhunt.com)
The epidermal growth factor receptor family (ERBB) is overexpressed in a wide variety of tumor types and is correlated with poor prognosis. (aacrjournals.org)
Intra-tumour IgA1 is common in cancer and is correlated with poor prognosis in bladder cancer. (lu.se)

Nodal positivity correlated with histological grade and tumour size, but not with estrogen receptor or c-erbB-2 status. (ispub.com)
Results of estrogen receptor and c-erbB-2 status using immunohistochemistry were documented. (ispub.com)
Chi square was used to test the association between ethnic group, tumour size (categorized as ≤2 cm, >2 cm and ≤5 cm, and >5 cm), histological grade, estrogen receptor (ER) status, c-erbB-2 status and lymph node metastases. (ispub.com)
Your Milliliters classifier was validated inside self-sufficient training (n = 40) along with affirmation (n = 109) cohorts discovering MSR, PSA, and also ISP to become associated with growth stage, lymph node reputation, Nottingham quality, stromal difference (SD), cancer dimension, excess estrogen receptor (Im), progesterone receptor (Public relations), and also receptor tyrosine-protein kinase erbB-2 (HER-2). (hif-signal.com)
Weak relationships were found between c-myc amplification and the presence of lymph-node metastasis, advanced stage, DNA non-diploidy and premenopausal status, but not tumor size, estrogen receptor or progesterone receptor status, or int-2 amplification. (lu.se)

The Her-2/ neu proto-oncogene, also known as c-erbB-2, is a member of the type I growth factor receptor gene family and is located in the long arm of chromosome 17 (17q12-21.32) [ 1 ]. (biomedcentral.com)
The c-myc proto-oncogene was analyzed in 311 cases of primary breast cancer, in 8% of which it was found to be amplified, usually at moderately increased copy number (2-5 copies). (lu.se)
C-myc amplification was significantly correlated to a high S-phase fraction and to amplification of the c-erbB-2 proto-oncogene. (lu.se)

Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation. (rcsb.org)
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. (lclabs.com)
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. (lclabs.com)
Clinical studies using ERBB inhibitors have focused on tumor growth effects, but ERBBs can contribute to malignancy independent of their effects on tumor growth. (aacrjournals.org)
Our studies were designed to evaluate the effect of ERBB inhibition on tumor cell motility and intravasation in vivo using clinically relevant small-molecule inhibitors. (aacrjournals.org)
Systemic treatment of hormone receptor-positive (HR+) breast cancer is undergoing a renaissance, with a number of targeted therapies including CDK4/6, mTOR, and PI3K inhibitors now approved for use in combination with endocrine therapies. (ox.ac.uk)

The gene symbol, ErbB, is derived from the name of a viral oncogene to which these receptors are homologous: erythroblastic leukemia viral oncogene. (wikipedia.org)
14 King C R, Kraus M H, Aaronson S A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. (thieme-connect.de)
Gene expression profiling of ErbB receptor and ligand-dependent transcription. (rochester.edu)
This gene, which encodes a member of the serine/threonine kinase family, regulates cell polarity and functions as a tumor suppressor. (cancerindex.org)
Mechanistically, EPB41L4A-AS2, acting at least in part as a tumor suppressor, upregulated tumor suppressor gene expression. (cancerindex.org)
Her-2/neu is an oncogene, which is a type of gene that can contribute to certain types of cancer. (medic8.com)
Normal cells have two copies of the Her-2/neu gene and low levels of Her-2 protein are produced on the surface of the cells. (medic8.com)
tumours that are associated with the Her-2/neu gene tend to be more aggressive and the outlook is generally not as positive. (medic8.com)
if the test for the gene is positive as well, this indicates that the patient is likely to have an aggressive tumour. (medic8.com)
The tumor suppressor p53 gene often is mutated in cancer, but not in HPV-associated tumors. (foodforbreastcancer.com)
A subset of patients with tumors having 2+ IHC results were found to show no response to the drug, whereas all those having gene amplification responded favorably. (biomedcentral.com)
Nevertheless, a negative (0 or 1+) or a 3+ Her-2/ neu IHC correlates well with a negative or positive Her-2/ neu gene amplification, respectively. (biomedcentral.com)
Her-2/ neu gene amplification is primarily detected by in situ hybridization and uses fluorescence (FISH) to detect the signals. (biomedcentral.com)
CISH is potentially able to detect Her-2/ neu gene amplification and to minimize, if not eliminate, the false positive fraction with the IHC procedure. (biomedcentral.com)
The adjacent pvt gene was co-amplified with c-myc in all tumors analyzed. (lu.se)
Gene amplification, on the other hand, is relatively infrequent and occurs mostly at low copy number, implying that tumors are heterogeneous with respect to cell clones harboring c-myc amplification. (lu.se)

This drug is currently approved in at least one country for the extended adjuvant treatment of adult patients with early stage HER-2-overexpressed/ampified brest cancer, to follow adjuvant trastuzumab-based therapy. (lclabs.com)
A tumour growth inhibition index (TGI) was calculated and relative TGIs calculated by dividing the TGI of control by that of trastuzumab-treated mice. (ox.ac.uk)
The uncorrected uptake of (111)In-DTPA-trastuzumab was associated with tumour response to trastuzumab. (ox.ac.uk)
The use of trastuzumab when given with chemotherapy improves response rates and progression-free and overall survival of patients with HER-2-positive metastatic breast cancer. (touchoncology.com)
It is a necessary adjunct in determining the subset of non-amplified IHC-positive invasive tumors that will not benefit from trastuzumab therapy. (biomedcentral.com)

The intracellular/cytoplasmic region of the ErbB receptor consists mainly of three subdomains: A juxtamembrane with approximately 40 residues, a kinase domain containing approximately 260 residues and a C-terminal domain of 220-350 amino acid residues that become activated via phosphorylation of its tyrosine residues that mediates interactions of other ErbB proteins and downstream signaling molecules. (wikipedia.org)
The ability ('+') or inability ('-') of each growth factor to activate each of the ErbB receptors is shown in the table below: The dimerization occurs after ligand bind to the extracellular domain of the ErbB monomers and monomer-monomer interaction establishes activating the activation loop in a kinase domain, that activates the further process of transphosphorylation of the specific tyrosine kinases in the kinase domain of ErbB's intracellular part. (wikipedia.org)
For the activation of kinase domain in the ErbB dimer, asymmetric kinase domain dimer of the two monomers is required with the intact asymmetric (N-C lobe) interface at the site of adjoining monomers. (wikipedia.org)
Activation of the tyrosine kinase domain leads to the activation of the whole range of downstream signaling pathways like PLCγ, ERK 1/2, p38 MAPK, PI3-K/Akt and more with the cell. (wikipedia.org)
Here, we show that plexin-B family members stably associate with the receptor tyrosine kinase ErbB-2. (rupress.org)
Binding of Sema4D to plexin-B1 stimulates the intrinsic tyrosine kinase activity of ErbB-2, resulting in the phosphorylation of both plexin-B1 and ErbB-2. (rupress.org)
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. (lclabs.com)
HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors. (lclabs.com)
Choline kinase (ChoK) is increased in human mammary tumors with high incidence, and this activation is associated with clinical variable indicators of greater malignancy. (aacrjournals.org)
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:2790960, PubMed:10805725, PubMed:27153536). (neobiotechnologies.com)
Its structure consists of an extracellular ligand-binding website a Alosetron single transmembrane hydrophobic helix and a cytoplasmic carboxy-terminal website to which tyrosine kinase activity is definitely limited.1 HER receptors are usually located in the basolateral membrane of the epithelial cells where they can interact with their ligands present in the stroma thus mediating signaling between the epithelium and the extra-cellular matrix. (ecolowood.com)
Following dimerization there is increased intracellular kinase activity of the receptor through a proximity effect resulting in phosphorylation of critical tyrosine residues on the cytoplasmic domain which then triggers the signal transduction cascade. (ecolowood.com)
Many other genetic targets are under active research in lung cancer, including Kirsten rat sarcoma viral oncogene homolog (KRAS), c-mesenchymal-epithelial transition receptor (c-Met), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and neurotrophic tyrosine receptor kinase (NTRK). (mdforlives.com)

The possibility of disease-free survival increases after resection of primary tumor and excision of isolated metastasis. (medscape.com)
Rat Muc4, a homologue of human MUC4, has been extensively studied in mammary gland tumours and has been shown to play an important role in epithelial growth, cell differentiation, cell-cell adhesion, metastasis, and tumour apoptosis. (bmj.com)
This may be because for many years, it has been assumed that the biomarker status of the primary tumor and its corresponding metastasis was not different. (springer.com)
This test filters circulating tumor cells from a patient's blood sample and gives a numerical probability of metastasis for colon, breast, prostate and ovarian adenocarcinomas. (dunphynunley.com)
2 There is only limited knowledge of the factors that predict for the development of CNS metastasis, but the main ones reported include young age, African ethnicity, oestrogen receptor (OR)-negativity, HER 2 -positivity, high tumour grade and BRCA 1 phenotype. (touchoncology.com)

The figure below shows the tridimensional structure of the ErbB family proteins, using the pdb files 1NQL (ErbB-1), 1S78 (ErbB-2), 1M6B (ErbB-3) and 2AHX (ErbB-4): The four members of the ErbB protein family are capable of forming homodimers, heterodimers, and possibly higher-order oligomers upon activation by a subset of potential growth factor ligands. (wikipedia.org)
The ligands to HER receptors (also known as epidermal growth factor [EGF] family of growth factors) are characterized by the presence of an EGF-like website (composed of three disulfide-bonded intramolecular organizations which confer binding specificity) and extra structural motifs (such as for example immunoglobulin-like domains heparin-binding sites and glycosilation sites). (ecolowood.com)

ErbB-1 and ErbB-2 are found in many human cancers, and their excessive signaling may be critical factors in the development and malignancy of these tumors. (wikipedia.org)
PJS is autosomal-dominant condition caused by mutations of STK11, characterized by gastrointestinal polyposis, mucocutaneous pigmentation, and predisposition to a range of epithelial cancers: including colorectal, gastric, pancreatic, breast, ovarian cancers and sex cord tumors with annular tubules). (cancerindex.org)

This finding could indicate that HER-2/neu expression is a new independent prognostic factor. (thieme-connect.de)
Next, the expression model, prognostic roles, potential biological functions and epigenetic regulation of tumor suppressor long noncoding RNAs were investigated and validated in the breast cancer and pancancer cohorts. (cancerindex.org)

Notably, the ErbB1 and ErbB4 are the two most studied and intact among the family of ErbB proteins, Which forms functional intracellular tyrosine kinases. (wikipedia.org)

We evaluated the duration of the drug effect after washing away free compound and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain. (rcsb.org)
The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells. (rcsb.org)
53% of TNBC patients express this antigen in at least 30% of their tumor cells. (oncotarget.com)
Cloning and characterization of T cell receptors (TCRs) from responding T cells resulted in the identification of the two HLA-A*0201-restricted T cell epitopes CXorf61 66-74 and CXorf61 79-87 . (oncotarget.com)
There are considerable evidences suggested that a hypercoagulable or prothrombotic state of malignancy occurs due to the ability of tumor cells to activate the coagulation system. (biomedres.us)
At present, a European lab offers a blood test which filters and isolates circulating tumor cells (a.k.a. micrometastatic cells) from a patient's blood, genetically fingerprints them, then pharmacogenetically tests the cells for the effectiveness of various medical therapies. (dunphynunley.com)
Here, we have investigated the role of ChoK in the development of breast cancer and found that ChoK is both necessary and sufficient for growth factor-induced proliferation in primary human mammary epithelial cells and an absolute requirement for the specific mitogenic response to heregulin in breast tumor-derived cells. (aacrjournals.org)
The FACE ErbB-2 (Y1248) and ErbB-2 (Y877) Kits were used to assay the levels of total and phosphorylated ErbB-2 contained within untreated or EGF treated A-431 cells. (activemotif.com)
Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins. (neobiotechnologies.com)
Altaher A, Adris M, Aliwaini S et al (2022) The Anticancer Effects of Novel Imidazo[1,2-a]Pyridine Compounds against HCC1937 Breast Cancer Cells. (dntb.gov.ua)

Blinded determinations of receptor status on paired samples were performed by immunohistochemistry and fluorescence in situ hybridization at a central laboratory and compared with those performed locally. (springer.com)

For example, ErbB-2 and ErbB-4 knockout mice die at midgestation leads to deficient cardiac function associated with a lack of myocardial ventricular trabeculation and display abnormal development of the peripheral nervous system. (wikipedia.org)
In ErbB-3 receptor mutant mice, they have less severe defects in the heart and thus are able to survive longer throughout embryogenesis. (wikipedia.org)

These results indicate that ERBB inhibition should be considered for blocking other tumor cell malignant properties besides growth. (aacrjournals.org)

The amplification of the HER-2 oncogene occurs in ~25% of breast cancer patients and is associated with diminished disease-free and overall survival. (touchoncology.com)

To view a multidisciplinary tumor board case discussion, see Memorial Sloan Kettering e-Tumor Boards: Metastatic Clear Cell Renal Cell Carcinoma . (medscape.com)
Patients with suspected diagnosis of locally recurrent or metastatic breast cancer, either at first relapse or after successive disease progressions, who had an appropriately preserved sample from a primary tumor and were scheduled for a biopsy of the recurrent lesion, were included. (springer.com)
It soon became clear that patients with HER-2-overexpressing metastatic breast cancer were at high risk of developing CNS involvement. (touchoncology.com)

We assessed Her-2/ neu alteration using CISH on formalin-fixed paraffin-embedded primary invasive ductal carcinoma tumors in which IHC (CB11 antibody) had previously been performed, and we compared the results with IHC. (biomedcentral.com)

Once the ligand binds to the extracellular domain the receptor undergoes a conformational change of this region which allows homodimerization or heterodimerization with another activated receptor of the HER family. (ecolowood.com)
These receptors convert signals received from the extracellular environment into cell decisions such as growth and survival C a process termed signal transduction. (researchhunt.com)

only 2 patients required surgical intervention for local progression or symptoms. (medscape.com)
The occurrence of thrombosis is often the first indicator of an underlying malignancy and patient data also demonstrates a close association between tumour progression and the development of a procoagulant profile, supporting the hypothesis that the activation of the blood coagulation system contributes to tumour aggressiveness and vice versa [1]. (biomedres.us)
These results demonstrate that ChoK plays an essential role in both normal human mammary epithelial cell proliferation and breast tumor progression. (aacrjournals.org)

Landscape of tumor suppressor long noncoding RNAs in breast cancer. (cancerindex.org)
The landscape and biological functions of tumor suppressor long noncoding RNAs in breast cancer are still unknown. (cancerindex.org)
Data from whole transcriptome sequencing of 33 breast specimens in the Harbin Medical University Cancer Center cohort and The Cancer Genome Atlas was applied to identify and validate the landscape of tumor suppressor long noncoding RNAs, which was further validated by The Cancer Genome Atlas pancancer data including 33 cancer types and 12,839 patients. (cancerindex.org)

Insufficient ErbB signaling in humans is associated with the development of neurodegenerative diseases, such as multiple sclerosis and Alzheimer's disease, while excessive ErbB signaling is associated with the development of a wide variety of types of solid tumor. (wikipedia.org)
Excessive ErbB signaling is associated with the development of a wide variety of types of solid tumor. (wikipedia.org)
It's hard to believe, but I actually did all of solid tumor oncology and Hodgkin disease for about 10 years. (medscape.com)

Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. (thieme-connect.de)
Each FACE ErbB-2 Kit provides 96 rxns each of 2 antibodies that enable you to monitor and compare the levels of both phosphorylated and total ErbB-2. (activemotif.com)

The total-ErbB-2 antibody supplied in the FACE ErbB-2 Kits recognizes ErbB-2 protein regardless of its phosphorylation site. (activemotif.com)

About 5% of breast carcinomas are positive for phospho-c- erb B-2/HER-2/ neu oncoprotein. (ihcworld.com)

In addition to plexins, various other proteins have been implicated either as receptors for semaphorins or as components of the semaphorin receptor complex ( Pasterkamp and Kolodkin, 2003 ). (rupress.org)
The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. (neobiotechnologies.com)
Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). (neobiotechnologies.com)

Assessment of F-MuLV-induced tumorigenesis reveals new candidate tumor genes including Pecam1, St7, and Prim2. (rochester.edu)

In spite of the relevance of receptor status, the choice of systemic treatment for advanced disease is more often based on the biological characteristics of the primary tumor at the time of initial diagnosis than of the recurrent lesion at the time of relapse. (springer.com)

The mean tumour size was 3.75 cm and 50.4% of cases were of histologic grade 3. (ispub.com)
High MSR was found being related to large tumor period, lower Internet, and high Nottingham histologic rating. (hif-signal.com)
We also compared age at diagnosis and tumor histologic grade with IHC and CISH Her-2/ neu . (biomedcentral.com)
Similarly, although the small group of well-differentiated tumors was apparently Her-2/ neu negative in both tests, no significant association was noted between any tumor histologic grade and either IHC or CISH results. (biomedcentral.com)
Her-2/ neu testing should be done on all breast cancer cases regardless of age at presentation and tumor histologic grade. (biomedcentral.com)

ErbB protein family signaling is important for development. (wikipedia.org)
All four ErbB receptor family members are nearly same in the structure having single-chain of modular glycoproteins. (wikipedia.org)
It is a complex process due to the domain specificity and nature of the members of ErbB family. (wikipedia.org)
Neratinib, also known as HKI-272, is considered to be a second-generation inhibitor of the ErbB family of receptor kinases. (lclabs.com)
The HER/ErbB family of receptor tyrosine kinases drives critical responses in normal physiology and cancer, and the expression levels of the various HER receptors are critical determinants of clinical outcomes. (researchhunt.com)
Author Summary A family of cell surface molecules called the HER receptor family plays important roles in normal physiology and cancer. (researchhunt.com)

The FACE ErbB-2 (Y877) Kit contains a phospho-ErbB-2 antibody that was raised in rabbit against a synthetic phospho-peptide corresponding to residues surrounding phosphorylated Tyr877 of human ErbB-2 and recognizes ErbB-2 only when phosphorylated at Tyr877. (activemotif.com)
Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. (neobiotechnologies.com)

The disease is associated with high morbidity and mortality especially as we tend to see more advanced stages of breast cancer in our part of the world ( 2 , 3 ). (ispub.com)
The histological type of breast cancer comprised 137 infiltrating ductal carcinoma (not otherwise specified), 4 invasive lobular carcinoma, 3 papillary, 2 mucinous, one each of medullary, tubular and inflammatory carcinoma, 27 ductal carcinoma in situ and 1 Non Hodgkin lymphoma. (ispub.com)
Breast cancer is the most frequent gynecological tumor. (thieme-connect.de)
Expression analyses of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients. (thieme-connect.de)
HER-2/neu amplification predicts poor survival in node-positive breast cancer. (thieme-connect.de)
In CXorf61-negative breast cancer cell lines CXorf61 expression is activated by treatment with the hypomethylating agent 5-aza-2′-deoxycytidine. (oncotarget.com)
Neratinib is active against HER-2-positive breast cancer in patients. (lclabs.com)
With the technological advances, we are able to characterize molecular subtypes [2] , [3] of breast cancer which has facilitated the development of molecularly targeted therapeutics. (carcinogenesis.com)
Finally, EPB41L4A-AS2 was selected to validate our novel finding, and the tumor suppressive roles of EPB41L4A-AS2 in breast cancer were examined. (cancerindex.org)
Venous thromboembolism (VTE) and cancer are strongly associated, as the local or systemic activation of blood coagulation can be produced by tumor products and favours tumor spread. (biomedres.us)
During the thrombophilic state observed in cancer patients of different origins, the presence of circulating TF-bearing MVs in plasma has been used to explain why cancer patients may present a thromboembolic event distant from the location of tumour development [1]. (biomedres.us)
Breast cancer is still one of the most important tumors among women in industrialized countries. (aacrjournals.org)
Because of this, ErbB-2 is one of the major drug targets for breast cancer and other cancer treatments. (activemotif.com)
While many factors are involved in the etiology of cancer, it has been clearly established that diet significantly impacts risk of this disease [ 1 , 2 , 3 ]. (mdpi.com)
We have identified anti-cancer effects of Huaier, and its unique characteristics of 1) no side effects or toxicity, 2) in dose dependent manner, 3) causing specific cancer cell death with simultaneous tissue regeneration, 4) miRNA-mediated transcriptional control on the rescue of multiple signal transduction, by dependent on individual genomic potential. (fortunejournals.com)
Recent advancement in technology enabled to cultivate those useful species in quantity, and quality-controlled distribution in the conventional granule forms has begun since 1970's, and currently Huaier is recognized widely as the patent anti-cancer drug in China (Chinese administration license No. Z-20000109) [2, 4, 5]. (fortunejournals.com)
The HER receptor expression profile is a critical determinant of cell behavior [6], [7], and outcomes in cancer pathology. (researchhunt.com)
It is generally accepted that HPV has a role in some cases of head and neck cancer, as well as anogenital tumors. (foodforbreastcancer.com)
When I finished my 5 years of pharmacy school, I took a part-time job as a cancer researcher at Roger Williams Hospital in Providence, Rhode Island, where I worked with Ellen Spremulli and Dan Dexter, who were very instrumental in the very beginnings of tumor biology . (medscape.com)
The frequency of the type of neoplasm was higher for lung cancer, followed by malignant colon tumor. (cdc.gov)
Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment. (cdc.gov)

One of the more important things is the status of the patient's tumor in regard to potential resectability. (medscape.com)

When considering only patients who had mastectomy or lumpectomy, the racial breakdown was 65 Chinese (60.7%), 30 Malay (28.0%) and 12 Indian (11.2%) The mean tumour size of infiltrating ductal carcinoma as measured in mastectomy and lumpectomy specimens (n = 107) was 3.75 cm (range 0.6 cm to 9.8 cm). (ispub.com)
The size of infiltrating ductal carcinoma (IDC) tumours at presentation is tabulated in table 1 and the histological grade of IDC, in table 2. (ispub.com)
Activation of HER-2 is frequent in ductal carcinoma in situ suggesting that HER-2 signaling plays a critical role in the early stages of breast tumorigenesis. (ihcworld.com)

The Y877 kit contains phospho-ErbB-2 antibody that recognizes ErbB-2 only when phosphorylated at Tyr877, while the Y1248 kit provides a phospho-antibody that recognizes ErbB-2 only when phosphorylated at Tyr1248. (activemotif.com)
Each kit contains a total-ErbB-2 antibody that recognizes ErbB-2 regardless of its phosphorylation state. (activemotif.com)
Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. (neobiotechnologies.com)

For other groups of patients with NSCLC, multiple drugs that have recently come on the market are in trials, depending on the genetics of their tumor type. (mdforlives.com)

Neratinib permanently inactivates the ErbB kinases. (her2support.org)

Anatomy15

Organisms8

Diseases78

Chemicals and Drugs65

Analytical, Diagnostic and Therapeutic Techniques and Equipment43

Phenomena and Processes50

Disciplines and Occupations1

Information Science4

Health Care7

HER240

EGFR33

Overexpression14

Human epidermal3

ERBB29

Biomarkers2

Prognosis7

Estrogen receptor5

Proto-oncogene3

Inhibitors6

Gene16

Trastuzumab5

Kinase13

Metastasis5

Ligands2

Cancers2

Prognostic2

ErbB11

Cells10

Immunohistochemistry1

Mice2

Inhibition1

Oncogene1

Metastatic3

Invasive ductal carcinoma1

Extracellular2

Progression3

Suppressor3

Solid tumor3

Antibodies2

Phosphorylation site1

Carcinomas1

Proteins3

Genes1

Primary tumor1

Histologic5

Family6

Residues2

Cancer21

Patient's1

Ductal3

Antibody3

Genetics1

Neratinib1